首页> 外文期刊>American Journal of PharmTech Research >Application of Fulvic Acid as a Pemeation Enhancer for Buccal Drug Delivery of Sumatriptan Succinate
【24h】

Application of Fulvic Acid as a Pemeation Enhancer for Buccal Drug Delivery of Sumatriptan Succinate

机译:黄腐酸作为舒马曲坦琥珀酸酯口腔药物递送的渗透促进剂的应用

获取原文
           

摘要

  ABSTRACT The aim of the present study was to prepare buccoadhesive sustained release tablets of sumatriptan succinate using novel permeation enhancer to release the drug for extended period of time with reduction in dosing frequency. In the present work sumatriptan succinate was used as a model drug and interaction studies performed using FTIR spectroscopy and DSC revealed that there was no drug, polymer and permeation enhancer interaction. Fulvic acid was extracted from shilajit by using resins. Fulvic acid was characterized by various spectroscopic techniques. Buccoadhesive sustained release tablets of sumatriptan succinate with novel permeation enhancer were prepared by direct compression method using bioadhesive polymers like carbopol 934 and HPMC. The physical characteristics like surface pH, swelling index, in vitro mucoadhesion strength, in vitro drug release and in vitro permeation of formulated tablets were shown to be dependent on characteristics and composition of bioadhesive materials used. The in vitro release study showed 99.88% of drug release with fulvic acid, respectively. Fulvic acid containing tablet has shown enhancement in permeation of drug of 93 % in 12 hours across buccal mucosa in comparison with plain sumatriptan succinate tablet. Sumatriptan succinate release from the buccoadhesive system was extended and exhibited a non fickian drug release kinetics approaching to first order as the values of release rate exponent varied between 0.97 to 0.99 resulting in a regulated and complete release until 8 hours. Keywords: Buccal drug delivery system, Sumatriptan succinate, Fulvic acid, In-vitro drug release, In-vitro permeation study.
机译:摘要本研究的目的是使用新型的渗透促进剂来制备舒马曲坦琥珀酸酯的粘膜粘附缓释片,以延长药物的释放时间,并降低给药频率。在目前的工作中,舒马普坦琥珀酸酯被用作模型药物,使用FTIR光谱和DSC进行的相互作用研究表明,没有药物,聚合物和渗透促进剂相互作用。使用树脂从shilajit中提取出富勒酸。黄腐酸通过各种光谱技术表征。采用卡波姆934和HPMC等生物粘附性聚合物,通过直接压片法制备了具有新型渗透促进剂的舒马曲坦琥珀酸酯的丁考胶粘剂缓释片。所显示的物理特性(如表面pH,溶胀指数,体外粘膜粘附强度,体外药物释放和体外渗透)取决于所用生物粘合剂材料的特性和组成。体外释放研究显示,富里酸分别释放99.88%的药物。与普通舒马曲坦琥珀酸盐片剂相比,含黄腐酸的片剂在12小时内在颊粘膜中的药物渗透性提高了93%。舒马曲坦琥珀酸酯从颊粘连系统中的释放得到扩展,并且显示出非一级药物释放动力学,接近一级,因为释放速率指数的值在0.97至0.99之间变化,从而导致稳定且完全的释放直至8小时。关键词:颊释药系统,琥珀酸舒马曲坦,黄腐酸,体外药物释放,体外渗透研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号